4/1/2026

Buprenorphine Hydrochloride Injection

Products Affected - Description

- Buprenorphine injection, Par Pharmaceuticals, 0.3 mg/mL, 1 mL vial, 5 count, NDC 42023-0179-05
- Buprenorphine injection, Pfizer, 0.3 mg/mL, 1 mL Carpuject syringe, 10 count, NDC 00409-2012-32

Reason for the Shortage

- Par did not provide a reason for the shortage.
- Pfizer has buprenorphine injection on shortage due to manufacturing delays.
- Somerset has buprenorphine injection available.

Available Products

- Buprenorphine injection, Somerset Therapeutics LLC, 0.3 mg/mL, 1 mL vial, 5 count, NDC 70069-0027-05

Estimated Resupply Dates

- Par has buprenorphine 0.3 mg/mL 1 mL Carpuject syringes on back order and the company estimates a release date of early-June 2026.
- Pfizer has buprenorphine 0.3 mg/mL 1 mL vials on back order and the company estimates a release date of March 2026.

Safety

- Pfizer, in coordination with FDA, issued an Important Drug Warning Letter regarding a potential molding defect at the tip of the needle sheath. Visually examine Carpuject® units prior to administration and discard any unit showing a hole at the tip of the needle sheath as shown in pictures at https://www.pfizerhospitalus.com/sites/default/files/news_announcements/Issued%20Carpuject%20DHCPL%2027MAR2026.pdf.

Updated

Updated April 1, 2026 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 30, 2026 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2026, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.